ERBB2 and breast cancer: Most women in the cohort presented with estrogen receptor (ER)–positive, ERBB2 (formerly HER2 or HER2/neu)–negative breast cancer (487 of 729 [66.8%]), while 15.4% of the cohort (112 of 729) had TNBC.